RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

January 04, 2023 at 08:05 AM EST

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to the Company’s lead clinical asset, RYZ101, which uses ²²⁵Ac-DOTATATE to treat somatostatin receptor-positive (SSTR+) tumors.

The USPTO has issued U.S. Patent No. 11,497,822 and U.S. Patent No. 11,541,134, which are directed to compositions that include ²²⁵Ac-DOTATATE and the use of these compositions to treat SSTR+ neuroendocrine tumors, respectively. Both patents are valid until 2042, without taking into account any potential patent term extension.

“RYZ101 is currently being evaluated in two clinical trials and is poised to be the first Ac225 based radiopharmaceutical drug for the industry,” said Ken Song, M.D., President and CEO of RayzeBio. “The recognition by the USPTO of our proprietary work with ²²⁵Ac-DOTATATE provides us valuable patent protection for the substantive investment we are making to bring forth this medicine to treat cancer patients.”

About RYZ101

RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. Details of the study can be found at https://clinicaltrials.gov/ct2/show/NCT05477576.

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.